Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)
ConditionMyopia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8+
SponsorCooperVision International Limited (CVIL)
About this trial
The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.
Eligibility criteria
Qualifiers
Patient contact lens refraction should fit within the available parameters of the study lenses (spherical power within -4.00D and the cylinder power within 1.50D).
Is willing to comply with the wear and visit schedule.
Is willing to participate and signed the informed consent form.
Disqualifiers
Age under 8 years old
Any ocular abnormalities, undergone corneal surgery, or history of ocular trauma, active corneal infections (corneal inflammation), corneal curvature less than 40.00D or more than 46.00D
Best corrected visual acuity less than 1.0D
Pregnant, lactating or near-pregnancy
Trial design
Treatments tested in this trial
- Paragon CRT®100 Contact Lens
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
CooperVision International Limited (CVIL)
Lead sponsor
TigerMed
Collaborator
Source ClinicalTrials.gov